San Diego-based Celladon
, a biopharmaceuticals firm developing a genetically targeted enzyme replacement therapy which helps in the treatment of late-stage, heart failure, has raised $53M in a second close of a funding round, the firm said today. The round came from new investors MPM Capital and LSP Life Sciences, along with Pfizer Venture Investors, Lundbeckfond Ventures, Novartis Venture Funds, Hambrecht and Quist Capital Management, GBS Venture Partners, Enterprise Partners Venture Capital, Johnson & Johnson Development Corp., and Venrock. Tod Foley of MPM Capital and Fouad Azzam of LSP Life Sciences Partners have joined the firm's board laong with the funding. The firm said the funding will go to establish a subsidiary in The Netherlands, along with other development.
posted on Monday, May 7, 2012 (Link to more information)
> Celladon Raises $30M
> Celladon Files For IPO
> Celladon Gains $21.8M
> Celladon Gets $43M For Heart Failure Treatments
> Enterprise Partners Promotes Zsebo To Venture Partner